What Analytical Testing Labs Find in 'Herbal' Weight Loss Raw Materials That a Supplier COA Will Never Show

FDA maintains a public database of dietary supplement products found to contain hidden pharmaceutical ingredients. As of mid-2026, that list exceeds 1,000 entries. Weight loss products account for the largest share — by a significant margin. And a substantial number of those products were marketed with the word “herbal” somewhere on the label.

That’s not a manufacturing defect in most cases. It’s deliberate adulteration introduced somewhere in the raw material supply chain — before the product ever reached a US blender or contract manufacturer. The brand that put its name on the bottle may have had no idea.

If your company sells anything in the weight management category, or if you source raw materials marketed for appetite control, thermogenesis, or fat metabolism support, you need to understand what analytical testing labs actually look for — and why a certificate of analysis from your supplier is structurally incapable of protecting you.

The Most Common Hidden Drug Adulterants in Weight Loss Raw Materials

The pharmaceutical adulterants showing up in “herbal” weight loss products aren’t random. There’s a relatively consistent shortlist, though it evolves as regulators identify and publicize new compounds.

Sibutramine leads the list. FDA withdrew it from the US market in October 2010 after post-market cardiovascular data showed unacceptable rates of heart attack and stroke in patients with pre-existing disease. That was 16 years ago. Analytical testing labs still find it. Published peer-reviewed surveys of weight loss products — including work published in Drug Testing and Analysis and JAMA Internal Medicine — consistently show sibutramine as the most frequently detected pharmaceutical compound across high-risk supplement samples, appearing in double-digit percentages of products tested in enforcement contexts. The compound is cheap to synthesize, has measurable pharmacological activity at doses as low as 1–2 mg, and is essentially undetectable through sensory inspection or standard UV-HPLC purity tests calibrated to botanical markers.

Phenolphthalein was pulled from OTC laxative formulations in 1999 after FDA cited potential carcinogenicity based on animal study data. It reappeared in weight loss products as a covert laxative adulterant — technically producing a measurable scale weight change, but with zero legitimate safety profile at unknown doses and no place in any food or supplement product.

DMAA (1,3-dimethylamylamine, also marketed as methylhexaneamine) is a synthetic stimulant originally patented as a nasal decongestant by Eli Lilly in 1944. It has no lawful use in dietary supplements under current FDA interpretations. The agency sent warning letters to more than a dozen companies for DMAA-containing products and explicitly rejected industry claims that DMAA could be characterized as a natural constituent of geranium oil. It still circulates in raw material blends positioned for energy and weight management, particularly in supply chains that serve both the sports nutrition and general wellness markets.

Lorcaserin (Belviq), FDA-approved in 2012 and voluntarily withdrawn in February 2020 due to cancer risk signals in long-term trials, has appeared in analytical testing lab findings on imported weight loss raw materials. Fenfluramine, withdrawn in 1997 as part of the fen-phen combination, remains detectable in some products. Both are Schedule IV controlled substances — their presence in a dietary supplement doesn’t just create a product liability problem; it creates a criminal exposure.

DNP (2,4-dinitrophenol) occupies a different tier of risk entirely. It works — catastrophically — by uncoupling mitochondrial oxidative phosphorylation and driving uncontrolled thermogenesis. Ambient body temperature can exceed lethal limits within hours of ingestion. Multiple deaths have been attributed to it in the US and UK. It circulates primarily in bodybuilding and extreme weight loss supply chains, but contamination risk at shared processing facilities is real.

Why a Standard Supplier COA Cannot Detect Any of This

This is the point that catches Midwest supplement brands off guard — particularly companies that are otherwise diligent about paperwork. The COA your overseas supplier provides may show botanical identity confirmation, moisture content within spec, heavy metals below USP limits, microbial counts within specification, and an HPLC assay confirming a standardized active marker (say, “45% hydroxycitric acid” for Garcinia cambogia). Every box ticked. Every number in range.

None of that tests for synthetic adulterants.

A polyphenol HPLC method is calibrated against specific reference standards for the analytes it’s designed to detect. Sibutramine running through that same column doesn’t trigger a flag — it elutes at a different retention time, at a wavelength where the detector isn’t looking for it, and the result is simply not reported. The test wasn’t designed for it. The method doesn’t know to look.

What actually detects pharmaceutical adulterants is liquid chromatography coupled with mass spectrometry: LC-MS/MS (triple quadrupole) for targeted compound screening, or LC-HRMS (high-resolution mass spectrometry, using QTOF or Orbitrap instruments) for untargeted broad-spectrum screening. Targeted methods can detect known adulterants at concentrations as low as 1–5 micrograms per kilogram — parts per billion sensitivity, with compound-specific confirmation via fragmentation patterns that make false positives essentially impossible. Untargeted screening goes further, flagging unexpected molecular features for investigation even when the compound isn’t in the reference library.

The troubling trend: some suppliers have started issuing COAs that include “adulterant free” as a listed specification with “pass” in the result column. No method is cited. No analyte list is provided. That’s documentation theater, not analytical data. It gives a brand something to put in its 21 CFR Part 111 file without actually testing anything.

Analytical testing laboratories that routinely handle high-risk supplement categories maintain validated methods covering 200–400+ adulterant compounds and update their reference libraries as novel analogs appear in FDA surveillance data and academic literature. Maintaining that kind of institutional knowledge — including the reference standard collection alone — is beyond the resource capacity of most supplement brands’ internal quality operations.

Where in the Supply Chain Adulteration Actually Happens

Not every overseas botanical supplier is intentionally adulterating product. The supply chain for herbal weight loss ingredients is long and multilayered, and contamination points are multiple.

In some cases, adulteration is deliberate at the extraction or concentration stage. A botanical extract manufacturer facing commercial pressure to demonstrate that their ingredient “works” — to justify premium pricing or support efficacy-adjacent marketing claims — adds a pharmaceutical compound to boost the physiological signal. The adulterated material then enters normal distribution channels with legitimate-looking documentation.

In other cases, adulteration happens at the trading or blending stage, where a low-cost ingredient broker pre-mixes a botanical proprietary blend that includes undisclosed pharmaceutical actives to hit a target price and claimed performance profile simultaneously. The primary ingredient on the COA is real. The adulterant isn’t listed.

And in a smaller number of cases — arguably the most insidious scenario for brands with otherwise clean supply chains — cross-contamination occurs at shared processing facilities in source countries where equipment used to process pharmaceutical actives isn’t adequately cleaned between production runs. That’s not fraud by your supplier; it’s a systemic manufacturing control failure that produces the same outcome.

The only way to know which situation you’re in is to test the material you actually received, using methods capable of detecting what you’re looking for.

Under 21 CFR Part 111.75, dietary supplement manufacturers are required to confirm the identity of every incoming component before use. But identity testing — even HPTLC or DNA barcoding — doesn’t address adulteration screening. Identity testing confirms you received Garcinia cambogia extract. It says nothing about whether sibutramine came along with it.

What a Defensible Testing Protocol Looks Like for Weight Loss Raw Materials

For any raw material destined for a weight management, thermogenic, or appetite control product, the minimum defensible incoming testing protocol covers four areas:

1. Botanical identity confirmation via HPTLC or DNA barcoding — to verify you received the declared species at the declared concentration, not a cheaper substitute
2. Targeted adulterant screening via LC-MS/MS against a validated compound library that includes sibutramine, DMAA, phenolphthalein, lorcaserin, fenfluramine, and current structural analogs appearing in FDA’s Dietary Supplement Ingredient Advisory List
3. Heavy metals by ICP-MS per USP <232>/<233> — separate from adulteration risk, but non-negotiable for herbal ingredients sourced from regions with elevated soil contamination
4. Microbial limits per USP <61>/<62> with targeted pathogen testing (E. coli, Salmonella, Staphylococcus aureus) appropriate for the intended use

The adulterant panel should be reviewed at minimum annually, or any time FDA posts a new tainted supplement notification in the weight loss category. Novel analogs — compounds structurally designed to evade established screening panels — appear with increasing frequency, and a panel that was comprehensive in 2024 may have meaningful gaps by late 2026.

Testing frequency is the other variable most brands underestimate. Screening one representative lot per supplier per year and treating the relationship as “validated” assumes that your supplier’s upstream sourcing is static. It rarely is. Lot-by-lot screening for high-risk categories, or at minimum quarterly testing for high-volume weight loss raw materials, is the standard FDA investigators look for during a 21 CFR Part 111 audit — and the standard that actually corresponds to the supply chain volatility in this ingredient category.

The Regulatory Exposure Is Asymmetric

The weight loss category is genuinely different from other herbal supplement segments on the enforcement risk dimension. The exposure for brands that distribute adulterated products is not proportional to intent or documentation quality.

FDA can mandate a recall. The FTC can pursue enforcement for marketing claims that functionally rely on the pharmacological effects of undisclosed drug ingredients — and has done so in multiple high-profile cases. Plaintiffs’ attorneys can file product liability suits, and class action risk in this space has produced settlements in the range of $10–50 million for brands that had no knowledge their raw material was adulterated. The documentation defense — “we requested COAs from our supplier” — has not succeeded as a shield in major enforcement actions in this category over the past decade.

The math isn’t particularly complicated. A robust incoming testing protocol for weight loss raw materials — identity, adulterant screening, heavy metals, and microbiology — costs a fraction of a single recall event measured in direct product destruction, regulatory response costs, legal fees, and lost retail shelf placement. Analytical testing labs exist precisely so brands don’t have to choose between affordability and defensibility.

If your weight loss raw material testing protocol hasn’t been audited against current FDA guidance and the current adulterant landscape, that’s where to start. The compound your supplier didn’t disclose doesn’t care about the paper trail you assembled.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days. Contact us

Related from our network

• ISO 17025-Accredited Supplement Testing: What Accreditation Actually Guarantees — Qalitex Laboratories operates under ISO 17025 accreditation; understand what that means for the legal defensibility of your test results.
• Supplement Label Accuracy Testing: When the Bottle Doesn’t Match the Lab Results — A deeper look at how potency verification and adulteration screening protect both brands and consumers.